Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Auburn tabs USF’s Alex Golesh as its next coach, replacing Hugh Freeze on the Plains
The 41-year-old Golesh, who was born in Russia and moved to the United State at age 7, is signing a six-year contract that averages more than $7 million annually to replace Hugh Freeze. Freeze was fired in early November after failing to fix Auburn’s offensive issues in three seasons on the Plains.
Alabama Power seeks to delay rate hike for new gas plant amid outcry
The state’s largest utility has proposed delaying the rate increase from its purchase of a $622 million natural gas plant until 2028.
Former U.S. Sen. Doug Jones announces run for Alabama governor
Jones announced his campaign Monday afternoon, hours after filing campaign paperwork with the Secretary of State's Office. His gubernatorial bid could set up a rematch with U.S. Sen. Tommy Tuberville, the Republican who defeated Jones in 2020 and is now running for governor.
Scorching Saturdays: The rising heat threat inside football stadiums
Excessive heat and more frequent medical incidents in Southern college football stadiums could be a warning sign for universities across the country.
The Gulf States Newsroom is hiring an Audio Editor
The Gulf States Newsroom is hiring an Audio Editor to join our award-winning team covering important regional stories across Mississippi, Alabama and Louisiana.
Judge orders new Alabama Senate map after ruling found racial gerrymandering
U.S. District Judge Anna Manasco, appointed by President Donald Trump during his first term, issued the ruling Monday putting a new court-selected map in place for the 2026 and 2030 elections.
